Management

George Schreiner, MD, PhD
Chief Executive Officer

Dr. Schreiner joined Raven in May 2006. He is experienced in all phases of drug development, from discovery through clinical development to commercial launch. Prior to joining Raven, Dr. Schreiner was Chief Scientific Officer and Chief Medical Officer at Scios until its acquisition by Johnson & Johnson, whereupon he was named President. In that capacity, he oversaw research and development programs at Scios in cardiovascular disease, inflammation, and oncology. He served on the Pharmaceutical Research and Development Committee for Johnson & Johnson and chaired its Early Research and Development Committee. Dr. Schreiner received his M.D. from Harvard Medical School and his Ph.D. in Immunology from Harvard University. He trained in Internal Medicine and Nephrology at the Brigham and Women’s Hospital in Boston. He held joint appointments on the faculties of the Department of Medicine and Pathology at Harvard Medical School and the Washington University School of Medicine, where he received tenure. He was one of the founding scientists at CV Therapeutics where he served as Vice President of Medical Science and Preclinical Research.

Return to top

Jennie P. Mather, PhD (Founder)
President and Chief Scientific Officer

Dr. Mather established Raven on pioneering research performed in her laboratory at Genentech. With more than 30 years of experience in cell culture and cell biology research, Dr. Mather is a recognized leader in the application of cell biology to technology and pharmaceutical product development. She has unusually broad experience that spans basic research in cancer biology and reproductive endocrinology. As an Assistant Professor at The Rockefeller University to applied research in development and product discovery at Genentech. Prior to founding Raven, Dr. Mather was a Staff Scientist for 15 years at Genentech, engaged in all phases of drug discovery and development, from project conception through scale-up and the development of potential new products. Dr. Mather led or participated in 12 project teams that produced a number of Genentech's marketed products, including Herceptin®, a monoclonal antibody for treatment of patients with metastatic breast cancer; Activase®, a biosynthetic form of the human tissue plasminogen activator (t-PA) for treatment of heart attack, acute ischemic stroke, and acute massive pulmonary embolism; Pulmozyme®, an inhalation solution for management of cystic fibrosis; and Genentech's anti-IgE antibody currently in late-stage clinical trials for asthma. Dr. Mather's work led to a number of breakthroughs in cell technology and several key patents for Genentech, including serum-free media for the commercial production of t-PA and other products, genetically engineered production cell lines, several tissue progenitor cell lines, and use patents on several Genentech pipeline products. She also contributed to the design of the cell culture biomanufacturing processes used for commercial production of four of Genentech's marketed protein therapeutics. Dr. Mather is an inventor on 30 issued patents, the author of more than 150 publications, and the author or editor of five books on animal cell culture. She is on the board of directors of Healthcare Businesswomen's Association and serves on the scientific advisory board of Springboard Enterprises as well as two bioscience companies. Dr. Mather is the recipient of the First Innovator of the Year Award from the Healthcare Businesswomen's Association (2003) and was named as one of the Top 10 Innovators for scientific and business aptitude by Red Herring Magazine (2002). She received a PhD from the University of California, San Diego and was an NIH-INSERM exchange scientist in Lyon, France.

Return to top

John B. Whelan, MBA
Chief Operating Officer and Chief Financial Officer

Prior to joining Raven, Mr. Whelan was Vice President and Chief Financial Officer at Eos Biotechnology, where he was responsible for finance, business development, and administration. While at Eos, Mr. Whelan completed a funding round and reached agreement to merge Eos with Pharmacopeia. He also worked on collaborations with Biogen, Medarex, ICOS, and Seattle Genetics. Previously, Mr. Whelan held a number of ascending management positions at Hewlett Packard/Agilent, culminating in his tenure as Director of Corporate Development, during which he led the consummation of numerous acquisitions, investments, and collaborations with companies in the life sciences, medical devices, and computing industries. He also led the team that completed HP's first $1 billion acquisition. Mr. Whelan has a BS in Engineering from the University of California, Berkeley and an MBA from the Anderson Graduate School of Management at UCLA.

Return to top

Carolyn R. Adler, JD
Vice President, Intellectual Property and Legal Affairs

For the past 20 years, Ms. Adler has counseled pharmaceutical and biotechnology companies on the full range of intellectual property, business development, research and development, and litigation issues, with particular focus on the strategic aspects of intellectual property law. Her expertise encompasses licensing and corporate partnering, research and development, manufacturing, clinical trials, product marketing, and disclosure and compliance. Prior to joining Raven, Ms. Adler led the intellectual property and general legal practice at COR Therapeutics Inc. for eight years, most recently as Vice President, Intellectual Property. Previous positions include five years as a patent attorney at Genentech, Inc. and several years as a legal consultant to biotechnology and pharmaceutical companies and in private practice. Ms. Adler received a BA from Brown University and was a research fellow at the National Cancer Institute. She received a JD from the SCALE Program at Southwestern University School of Law.

Return to top

Lucille W.S. Chang, PhD
Vice President, Manufacturing Operations

Dr. Chang brings to Raven more than 15 years of experience in taking protein therapeutics from the preclinical research stage through production for clinical trials, with specific expertise in commercial scale-up of biopharmaceutical manufacturing facilities, process development and optimization, quality assurance and quality control, Good Laboratory Practices and Good Manufacturing Practices compliance and oversight, analytical methods development, regulatory submissions, and management of preclinical, clinical, production, and contract manufacturing and testing. Dr. Chang has worked on more than 20 preclinical and clinical drug development projects and numerous regulatory submissions. Prior to joining Raven, she was Vice President of Operations at GeneTrol Biotherapeutics, Inc. Her previous positions include Senior Director of Quality Systems and Analytical Development at Coulter Pharmaceutical, Inc., Director of Quality Control at SyStemix, Inc., and Manager of the BioProcess Control Virology Laboratory at XOMA Corp. Dr. Chang received a PhD in Microbiology from the University of California, Davis and a BA in Biochemistry from the University of California, Berkeley.

Return to top

Stanford J. Stewart, MD
Vice President, Clinical research

Dr. Stewart trained in Medical Oncology at Stanford University, then served as a member of the faculty of the School of Medicine at Vanderbilt University for more than twelve years. He has more than eight years of experience in the biotechnology industry, joining Matrix Pharmaceutical, Inc. in 1997 as Associate Medical Director. From 1998 until 2001, he was Clinical Scientist on the Herceptin project at Genentech where he guided post-marketing clinical development including the adjuvant breast cancer program. He moved to ALZA Corporation as Senior Medical Director. From 2001 to 2005, he was employed at Corixa Corporation where he rose from Senior Medical Director to Vice President, Clinical Research. Dr. Stewart holds a B.A. degree from Rice University, and an M.D. from Baylor College of Medicine. In addition to training in Medical Oncology, he did postdoctoral medical training in Internal Medicine at Case Western Reserve University and postdoctoral scientific training in the laboratory of Dr. Ronald Levy at Stanford University.

Return to top